From the discovery of IgE to the in-depth characterization of Th2 cells and ILC2, allergic inflammation has been extensively addressed to find potential therapeutical targets. To date, omalizumab, an anti-IgE monoclonal antibody, and dupilumab, an anti-IL-4 receptor alpha monoclonal antibody, represent two pillars of biologic therapy of allergic inflammation. Their increasing indications and long-term follow-up studies are shaping the many different faces of allergy. At the same time, their limitations are showing the intricate pathogenesis of allergic diseases.
Therapeutical Targets in Allergic Inflammation / Salvati, Lorenzo; Liotta, Francesco; Annunziato, Francesco; Cosmi, Lorenzo. - In: BIOMEDICINES. - ISSN 2227-9059. - ELETTRONICO. - 10:(2022), pp. 0-0. [10.3390/biomedicines10112874]
Therapeutical Targets in Allergic Inflammation
Salvati, Lorenzo;Liotta, Francesco;Annunziato, Francesco;Cosmi, Lorenzo
2022
Abstract
From the discovery of IgE to the in-depth characterization of Th2 cells and ILC2, allergic inflammation has been extensively addressed to find potential therapeutical targets. To date, omalizumab, an anti-IgE monoclonal antibody, and dupilumab, an anti-IL-4 receptor alpha monoclonal antibody, represent two pillars of biologic therapy of allergic inflammation. Their increasing indications and long-term follow-up studies are shaping the many different faces of allergy. At the same time, their limitations are showing the intricate pathogenesis of allergic diseases.File | Dimensione | Formato | |
---|---|---|---|
biomedicines-10-02874-v2.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
922.23 kB
Formato
Adobe PDF
|
922.23 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.